Letter to the editor re: Cabrera et al., 2019 'The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid'
- PMID: 31789892
- DOI: 10.1097/QAD.0000000000002407
Letter to the editor re: Cabrera et al., 2019 'The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid'
Comment on
-
The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid.AIDS. 2019 Nov 1;33(13):1967-1976. doi: 10.1097/QAD.0000000000002289. AIDS. 2019. PMID: 31259764 Free PMC article.
References
-
- Cabrera RM, Souder JP, Steele JW, Yeo L, Tukeman G, Gorelick DA, et al. The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid. AIDS 2019; 33:1967–1976.
-
- Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018; 379:979–981.
-
- Kawamura Y, Matsumoto K, Sato K. Stability of the reproductive variables and fetal malformations from control animals and animals treated with thalidomide in K bl: JW rabbits over two decades. Congenital Anomalies 2012; 52:191–202.
-
- Kuwagata M, Sakai Y, Tanaka S, Takashima H, Katagiri R, Matsuoka T, et al. Historical control data on developmental toxicity studies in rats. Congenital Anomalies 2019; 59:125–131.
-
- Piersma AH, Genschow E, Verhoef A, Spanjersberg MQ, Brown NA, Brady M, et al. Validation of the postimplantation rat whole-embryo culture test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 2004; 32:275–307.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
